Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: MCV4 vaccine - Novartis; MenACWY-CRM; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Tianjin CanSino Biotechnology
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 06 Dec 2016 GlaxoSmithKline plans a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA (IM) (NCT02986854)
  • 01 Dec 2016 GlaxoSmithKline initiates a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA (IM) (NCT02986854)
  • 01 Oct 2016 Novartis completes a phase IIIb trial for Meningococcal infections (prevention, healthy infants) in Argentina and Mexico (NCT02106390)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top